Log in

Relevant bibliographies by topics / Drug beroduat

Contents

Journal articles

Academic literature on the topic 'Drug beroduat'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Drug beroduat.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Drug beroduat"

1

Balunov, Р. A., and A. N. Khitrov. "Pharmacoeconomic aspects of the use of bronchodilators in the management of COPD: real clinical practice." Medical Council, no. 21 (January 20, 2019): 96–104. http://dx.doi.org/10.21518/2079-701x-2018-21-96-104.

Full text

Abstract:

Today, chronic obstructive pulmonary disease is the fourth global cause of deaths worldwide. A number of studies showed that 11 to 16 million people might suffer from the chronic obstructive pulmonary disease in Russia. The prevalence and high mortality of this disease lead to a significant socio-economic burden. A pharmacoeconomic comparison of two alternative drug technologies in the studied groups grants the reasonable opportunity to transfer patients to the domestic analogues, confirming that efficiency unit costs for using Tiotropium-native and Ipraterol-native are lower than the same cos

APA, Harvard, Vancouver, ISO, and other styles

2

Kazakov, Yu M., T. V. Nastroga, N. M. Motorna, O. E. Kitura, and N. L. Sokolyuk. "Optimised Complex Therapy of Chronic Obstructive Pulmonary Disease Exacerbation in Elderly Patients (Review)." Tuberculosis, Lung Diseases, HIV Infection, no. 2 (May 29, 2025): 101–5. https://doi.org/10.30978/tb2025-2-101.

Full text

Abstract:

Chronic obstructive pulmonary disease (COPD) is one of the most important medical and social problems, as it ranks third among the leading causes of death worldwide. Objective — to optimise the treatment of elderly patients with COPD, GOLD II, group B, using sequential nebuliser delivery of the mucolytic drug acetylcysteine and the respiratory cytoprotector ectoine (ectobrise) against the background of basic therapy. Materials and methods. 60 elderly patients with COPD, group B, were observed. Patients in the control group (n = 30) received complex basic therapy, which included an antibacteria

APA, Harvard, Vancouver, ISO, and other styles

3

Y. M. Mostovoy, Y. M., T. V. Konstantinovych, O. R. Lindiuk, and O. V. Bugaichuk. "RECOMMENDATIONS ON COPD AND FAMILY PRACTITIONERS: WHAT IS THE LEVEL OF ADHERENCE?" Ukrainian Pulmonology Journal 29, no. 4 (2021): 15–18. http://dx.doi.org/10.31215/2306-4927-2021-29-4-15-18.

Full text

Abstract:

Y. M. Mostovoy, T. V. Konstantinovych, O. R. Lindiuk, O. V. Bugaichuk Abstract Majority of COPD patients should receive medical care provided by family practitioners. Only the cases of severe, uncontrolled diseases must be managed by pulmonologists. That is why family practitioners must be well informed on actual requirements on diagnosis and treatment of COPD in order to give effective care to this population of patients. Following the aim to study quality of medical care, provided to COPD patients by family practitioners, we analyzed 220 out-patient records (95 men (43,2 %), 125 women (56,8

APA, Harvard, Vancouver, ISO, and other styles

4

Kirieieva, T. V., N. K. Kravchenko, and B. O. Basina. "STANDARDS FOR TREATMENT OF PATIENTS WITH COPD IN 2024: PLACE FOR TIOTROPIUM BROMIDE." Ukrainian Pulmonology Journal 32, no. 2 (2024): 55–58. http://dx.doi.org/10.31215/2306-4927-2024-32-2-55-58.

Full text

Abstract:

Updated GOLD 2024 guidelines emphasized the problem of insufficient or inaccurate diagnosis of COPD, leading to inappropriate therapy of these patients. This trend is also widespread in Ukraine, despite the significant improvement in diagnosis and available treatment options. The aim of the study was to determine the effectiveness of tiotropium bromide (Spiriva® HandiHaler® "Boehringer Ingelheim Pharma GmbH", Germany) for the initial and follow-up treatment of patients. We evaluated the effect of the drug on the clinical and functional status of patients and adherence to therapy. Materials and

APA, Harvard, Vancouver, ISO, and other styles

5

L.V., Kadomtseva, Daminov R.U., Valieva T.A., Mirzakarimova F.R., and Kaleda S.P. "USE OF NEBULIZER THERAPY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CARDIOVASCULAR COMORBIDITY." May 6, 2025. https://doi.org/10.5281/zenodo.15347598.

Full text

Abstract:

<em>Chronic obstructive pulmonary disease (COPD) is characterized by persistent and usually progressive airflow limitation associated with various risk factors, the main one being tobacco smoking. The increasing role of this pathology among the causes of morbidity and mortality is well known. It should be noted that in recent years there has been a greater understanding of the complexity of this disease in terms of an integrated clinical assessment of severity, pathophysiology and relationship with other pathologies. Chronic obstructive pulmonary disease is a disease of the second half of life

APA, Harvard, Vancouver, ISO, and other styles

6

Zherebtsova, N. Yu, and T. V. Kajdanek. "Local and systemic adverse reactions following COVID-19 vaccine (clinical report)." Russian Journal of Infection and Immunity, May 12, 2022. http://dx.doi.org/10.15789/2220-7619-las-1817.

Full text

Abstract:

The mass vaccination against novel coronavirus infection (COVID-19) requires to dynamically evaluate risks of adverse events following immunization to prevent them and develop vaccination tactics for various population groups. We describe a clinical case of reaction following administration of the second dose of the heterologous recombinant adenovirus based COVID-19 vaccine Gam-COVID-Vac (Sputnik V) in 48-year-old female healthcare worker. No adverse events after administration of the first dose were recorded. After vaccination, the patient complained of weakness, malaise, headache, loss of ap

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!